Description

Body Pharm AOD 9604 2mg: Benefits, Dosage & Fat Loss

Body Pharm AOD 9604 2mg is a synthetic 16-amino-acid fragment of human growth hormone (hGH) (residues 177–191), sold in South Africa as a research-grade lyophilised peptide for targeted lipolysis (fat breakdown) without the insulin-like growth factor 1 (IGF-1) spike or appetite suppression of glucagon-like peptide-1 (GLP-1) agonists like semaglutide.

What you’ll learn in this article:

1. How AOD 9604 triggers fat loss at the receptor level, and why that mechanism differs from GLP-1s and full hGH.
2. A practical 2026 reconstitution and dosing protocol for the Body Pharm 2mg vial.
3. The current South African regulatory position, side-effect profile, and where AOD 9604 fits against semaglutide and retatrutide.

Key Takeaways

• Active: AOD 9604, 2mg lyophilised vial, Body Pharm-branded.
• Mechanism: stimulates beta-3 adrenergic receptor (β3-AR) lipolysis; does not raise blood glucose or IGF-1 (Heffernan et al., Endocrinology, 2001).
• Typical dose: 300mcg subcutaneous injection, fasted, 5 days on / 2 off.
• Reconstitution: 1ml bacteriostatic water yields 2000mcg/ml; 2ml yields 1000mcg/ml.
• Best human data: Phase 2b trial, 300 obese patients, 12 weeks, modest fat reduction (news-medical.net, 2004); no newer randomised controlled trials (RCTs) since.
• Regulatory: not registered with the South African Health Products Regulatory Authority (SAHPRA) for weight loss; treat as a research compound. This caveat is not repeated below.

What Is Body Pharm AOD 9604 2mg?

Body Pharm AOD 9604 2mg is a 16-amino-acid synthetic peptide replicating residues 177–191 of the hGH C-terminus, supplied as a lyophilised powder in a single 2mg vial for subcutaneous use after reconstitution. Metabolic Pharmaceuticals (Melbourne) engineered the fragment in the late 1990s to isolate hGH’s lipolytic tail without the IGF-1 spike, hyperglycaemia, or tissue growth signalling of the full 191-residue molecule (Heffernan et al., Endocrinology, 2001). The literature also calls the molecule hGH fragment 176–191.

The Body Pharm label is a South African–distributed research peptide brand carrying the standard underground-lab format buyers will recognise from adjacent products like the Body Pharm CJC1295 & Ipamorelin 20 Pen. Practical specs:

• Format: lyophilised white powder, 2mg per vial.
• Reconstitution: 1ml bacteriostatic water yields 2000mcg/ml; 2ml yields 1000mcg/ml.
• Route: subcutaneous injection, insulin syringe.
• Storage pre-mix: room temperature, dry.
• Storage post-mix: refrigerated, used within 30 days.
• Status: research compound; sits alongside other weight loss injections available in South Africa but in a separate regulatory category from prescription GLP-1s.

A common buyer concern: “Is this the same molecule as the AOD discussed in older Australian trials?” Yes. The Body Pharm vial reproduces the same 176–191 sequence used in the Metabolic Pharmaceuticals studies; the difference is regulatory grade and manufacturer, not chemistry.

How AOD 9604 Works: The Fat-Loss Mechanism

AOD 9604 triggers fat breakdown by mimicking the lipolytic C-terminus of hGH. The fragment stimulates lipolysis and inhibits lipogenesis through a β3-AR pathway in adipose tissue, without binding the GH receptor or elevating IGF-1 (Heffernan et al., Endocrinology, 2001).

That receptor selectivity is the entire reason the fragment exists. The 2001 rodent study used obese and β3-AR knockout mice. AOD 9604 reduced adipose mass and increased fat oxidation in wild-type animals, but the effect disappeared in knockouts. That pattern confirms β3-AR as the operative pathway. Glucose tolerance and insulin sensitivity stayed flat at therapeutic doses (Heffernan et al., 2001).

Practical implications for a buyer comparing AOD 9604 against the full GH cascade or a Body Pharm CJC1295 & Ipamorelin 20 Pen protocol:

• No IGF-1 elevation, distinguishing the fragment from somatropin and from growth hormone-releasing hormone (GHRH) and growth hormone-releasing peptide (GHRP) secretagogues such as CJC1295 and ipamorelin.
• No hyperglycaemia signal at standard 300–500 mcg doses (rodent data, 2001).
• β3-AR-mediated lipolysis localised to adipocytes, not systemic anabolism.
• Safety profile drawn from six Metabolic Pharmaceuticals human trials enrolling 900+ participants through 2007, with adverse events comparable to placebo [stale, pre-2020 data].
• No muscle, bone, or cartilage growth signal, narrower than full hGH and narrower than CJC1295 plus ipamorelin.

A reasonable objection here: “If the human data is this old, why use it at all?” The mechanism is well-characterised at the receptor level; what remains modest and dated is the magnitude of clinical fat loss measured in trials. Buyers should treat the mechanism as established and the effect size as moderate.

AOD 9604 Benefits for Weight Management

AOD 9604 delivers targeted lipolysis without the IGF-1 elevation, hyperglycaemia, or muscle and cartilage hypertrophy associated with full somatropin. The benefit profile is narrow by design. That narrowness is the point for buyers who want fat loss without the broader endocrine footprint of hGH or a Body Pharm CJC1295 & Ipamorelin 20 Pen stack.

What the evidence base supports:

• Preferential reduction of visceral and subcutaneous abdominal adipose tissue via β3-AR-mediated lipolysis (Heffernan et al., Endocrinology, 2001).
• No IGF-1 spike, no anabolic signalling, separating the fragment cleanly from hGH and GH secretagogue protocols.
• Neutral on fasting glucose and insulin sensitivity at 300–500 mcg therapeutic doses (rodent data, 2001).
• Adverse events comparable to placebo across six Metabolic Pharmaceuticals trials (~900 participants through 2007) [stale].
• Emerging secondary signal in cartilage and joint repair, flagged by Paragon Sports Medicine under “Weight Support & Joint Health” in 2024; preliminary, not an approved indication.

A common reader objection: “Is this going to match what semaglutide does on the scale?” No. Human obesity endpoint data ends with the 2004 Phase IIb readout (12-week, 300 patients, modest dose-dependent fat loss) [stale]. AOD 9604 functions as an adjunct to a sustained caloric deficit and resistance training, not a replacement for either, and sits alongside the broader weight loss injections available in South Africa rather than competing with GLP-1s on magnitude.

AOD 9604 Dosage Instructions (2026 Protocol)

Standard AOD 9604 dosing sits at 300–600 mcg per day via subcutaneous injection into the abdomen, thigh, or upper arm in a fasted state. Most users dose first thing in the morning or pre-workout, because elevated insulin blunts the lipolytic signal. The cause-and-effect link matters: insulin drives substrate storage, which directly opposes the β3-AR lipolysis AOD 9604 triggers, so a fed-state dose wastes the window.

Body Pharm AOD 9604 2mg reconstitution and dosing at a glance:

• Reconstitution: Add 2 mL bacteriostatic water (0.9% benzyl alcohol) to the 2mg vial. Final concentration: 1000 mcg/mL.
• 300 mcg dose: Draw 0.3 mL (30 units on a U-100 insulin syringe).
• 500 mcg dose: Draw 0.5 mL (50 units).
• 600 mcg dose: Draw 0.6 mL (60 units), or split as 2 × 300 mcg (AM fasted, pre-second meal).
• Frequency: Once daily at 300 mcg. Split twice daily once you push past 400 mcg, given the ~30-minute plasma half-life reported by Ng et al., Obesity Research & Clinical Practice, 2006 [stale].
• Cycle: 8–12 weeks on, 4 weeks off. Reassess body composition before re-running.
• Storage: Reconstituted vial refrigerated at 2–8°C, used within 30 days.
• Site rotation: rotate week to week to avoid lipoatrophy at any single pinch.

A frequent concern: “Will I feel anything from a 300 mcg dose?” Most users report no acute sensation. AOD 9604 does not produce the rush of a stimulant or the satiety shift of a GLP-1; the readout is body composition over weeks, not subjective feedback within hours.

Stack discussions, including pairing with a Body Pharm CJC1295 & Ipamorelin 20 Pen or other weight loss injections available in South Africa, belong in a separate conversation with a registered practitioner, not a self-prescribed protocol.

AOD 9604 Side Effects and Safety Profile

AOD 9604’s side-effect profile is mild relative to hGH analogues and GLP-1 agonists, with most reported adverse events limited to transient injection-site reactions. As a result, the compound showed no androgenic activity, no oestrogenic activity, and no measurable IGF-1 elevation across Metabolic Pharmaceuticals’ Phase II programme (Ng et al., Obesity Research & Clinical Practice, 2006) [stale, pre-2023 data].

What the trial database supports, and what shows up in practice:

• Injection-site redness, swelling, or mild bruising, usually resolves within 24 hours. Rotate sites weekly.
• Transient nausea or mild dizziness in the first 3–5 days, typically at 500–600 mcg doses.
• Hypoglycaemia risk is low but real for diabetic users, fasted-training users, or anyone stacking with insulin-sensitising compounds. Monitor blood glucose for the first week.
• Plasma half-life is approximately 30 minutes (Ng et al., 2006) [stale], the rationale for splitting doses above 400 mcg.

A reasonable user objection: “What about long-term safety?” Long-term human safety data beyond 12 weeks remains limited as of 2026, and no manufacturer-backed trials have been published since the Phase III programme wound down. Athletes in World Anti-Doping Agency (WADA)-tested sport should request a formal ruling from their national anti-doping body before use; “not explicitly listed” is not the same as “permitted.” For stacking context, the Body Pharm CJC1295 & Ipamorelin 20 Pen sits alongside other weight loss injections available in South Africa in the same risk-tier conversation.

AOD 9604 vs Semaglutide vs Retatrutide: 2026 Comparison

AOD 9604 occupies a narrower niche than the GLP-1 class. The fragment drives lipolysis without touching appetite, gastric emptying, or insulin secretion. The choice is less about “which is strongest” and more about which mechanism matches your physiology and tolerance profile.

Who picks what

AOD 9604 suits users who eat well, train consistently, and want a lipolytic nudge without gastrointestinal side effects, satiety blunting, or the muscle and bone loss flagged in GLP-1 literature compared with non-pharmacological caloric deficit. In contrast, semaglutide and retatrutide suit users whose primary barrier is intake volume, not body recomposition. Tolerance also matters: GLP-1 nausea pushes a meaningful minority of users off semaglutide entirely.

A common objection: “Why not just take the strongest option?” Because the strongest appetite-suppressing option is not the right tool when your problem is not appetite. Mismatched mechanisms produce side effects without proportional benefit.

Stacking in practice

The most common 2025–2026 community protocol pairs AOD 9604 with a GH secretagogue rather than a GLP-1, using the Body Pharm CJC1295 & Ipamorelin 20 Pen for the secretagogue arm and AOD 9604 for daytime lipolysis. AOD 9604 plus GLP-1 combinations circulate anecdotally to offset GLP-1 lean-mass loss, however no controlled trial data supports the combination as of early 2026 [unverified].

Regulatory Status in South Africa (2026)

AOD 9604 is not a SAHPRA-registered medicine in South Africa as of early 2026, and the peptide has no United States Food and Drug Administration (FDA) approval for weight loss or any other therapeutic indication. Beskinny supplies Body Pharm AOD 9604 2mg as a research peptide only.

• SAHPRA status: No standalone registration on the SAHPRA medicines register as of early 2026 [unverified]. Unregistered peptides sit in a legal grey zone under the Medicines and Related Substances Act 101 of 1965.
• FDA status: Not approved as a drug. Holds Generally Recognized as Safe (GRAS) notification status for a separate cosmetic and food use only, not for injectable fat loss.
• WADA: Not explicitly named on the 2025 or 2026 Prohibited List, but S0 (non-approved substances) and S2 (peptide hormones) catch-all clauses likely apply.
• Practical step: Consult a registered SA healthcare practitioner before reconstituting any vial, and review this section if SAHPRA issues post-2026 guidance.

A direct buyer concern: “Could I get into trouble for ordering this?” Personal-use research peptide purchases sit in an unsettled enforcement zone. The compound is not a scheduled substance, but unregistered-medicines law gives SAHPRA discretion. For context on what is registered or imported under prescription locally, see weight loss injections available in South Africa. Stack candidates like the Body Pharm CJC1295 & Ipamorelin 20 Pen carry the same research-use framing.

Why Buy Body Pharm AOD 9604 from Beskinny?

Body Pharm AOD 9604 2mg is in stock at Beskinny at R350 per vial (2026), shipped from a South African warehouse with tracked courier delivery to all major metros within 2–4 business days.

• Product spec: 2mg lyophilised AOD 9604 per vial, Body Pharm branded, sealed with batch identifier. Reconstitute with 1–2 mL bacteriostatic water as covered earlier.
• Current stock: 19 vials available at time of writing (live count on the product page is the source of truth).
• Why Beskinny: dedicated South African peptide and weight loss injections retailer, not a general supplement reseller. Narrower SKU range, faster turnover, fresher stock.
• Stack buyers: the Body Pharm CJC1295 & Ipamorelin 20 Pen is the most-paired SKU; MOTS-C and Somatropin hGH pens sit in the same category for users building a longer GH-axis protocol.

A frequent concern at this stage: “What if I receive a damaged or short-dated vial?” Beskinny’s product page lists batch identifiers and replaces compromised stock on receipt evidence; raise the issue before reconstituting.

Order Body Pharm AOD 9604 2mg now at R350/vial. Check live stock and add to cart on the Beskinny product page.

Frequently Asked Questions

Short answers to the questions buyers ask before checkout.

How long until results show with AOD 9604?

Most research protocols run 8–12 weeks. The 2004 Phase IIb readout in 300 obese patients showed modest dose-dependent fat reduction over 12 weeks (news-medical.net, 2004), and no peer-reviewed human RCT has established a standardised timeline since. Results track diet adherence and training volume more than they track the peptide itself.

Can I stack AOD 9604 with other peptides?

Yes. The most commonly paired stack is a GH secretagogue like the Body Pharm CJC1295 & Ipamorelin 20 Pen, run alongside AOD 9604 for combined pulsatile GH release and direct lipolytic activity. No controlled human trial has tested the combination; protocols are community-derived.

Does AOD 9604 need refrigeration?

The lyophilised peptide stays stable at room temperature for shipping and short-term storage. Once reconstituted with bacteriostatic water, refrigerate the solution at 2–8°C and use within 28 days, the standard limit for benzyl-alcohol-preserved peptide solutions.

Is AOD 9604 detectable in drug tests?

AOD 9604 is not explicitly named on the WADA 2025 Prohibited List effective January 1, 2025. The compound may still fall under S2 (peptide hormones) or S0 (non-approved substances) catch-all clauses; competing athletes should obtain a written ruling from their national anti-doping body.

What is the half-life of AOD 9604?

Approximately 30 minutes following subcutaneous injection (Ng et al., Obesity Research & Clinical Practice, 2006). The short half-life is why split daily dosing (morning fasted plus pre-training) is the standard approach across weight loss injections available in South Africa.

Is AOD 9604 legal to buy in South Africa?

AOD 9604 is not SAHPRA-registered, which places the peptide in a legal grey zone under the Medicines and Related Substances Act 101 of 1965. Beskinny supplies Body Pharm AOD 9604 2mg as a research peptide only, and personal therapeutic use should be discussed with a registered SA practitioner.

Next step: Check live stock and pricing on the Beskinny product page when AOD 9604 fits your goals, and book a consult with a registered SA practitioner before reconstituting your first vial.

Editor’s notes / unresolved conflicts:

• Pronoun clarity: replaced ambiguous “it” references (referring to AOD 9604/the fragment/the compound/the peptide) with explicit nouns throughout, especially in section openers and bullet leads.
• “If” openers: rephrased the closing “If AOD 9604 fits your goals…” sentence and the FAQ “It may still fall…” to start more directly.
• Date formatting: “1 January 2025” changed to “January 1, 2025” per the Month Day, Year rule. The “Last updated: February 2026” line lacks a day; left as-is because no day was given in the source and inventing one would alter a factual claim.
• Transitions: added “As a result,” “In contrast,” and “however” at section/sentence junctions where flow needed it, without overusing banned transition openers.
• “[stale]” and “[unverified]” tags retained on factual claims to mark genuine evidentiary uncertainty.
• All internal links and external citations (Heffernan 2001, news-medical.net 2004, SAHPRA register, WADA list) preserved unchanged. Link-health verification is outside this revision’s scope.
• Acronyms (hGH, IGF-1, GLP-1, β3-AR, RCT, SAHPRA, FDA, GRAS, WADA, GHRH, GHRP) spelled out on first use; subsequent mentions use the abbreviation.